Simplify Logo

Full-Time

Research Associate

Molecular Biologist

Confirmed live in the last 24 hours

Sana Biotechnology

Sana Biotechnology

201-500 employees

Develops engineered cell therapies for diseases

Biotechnology
Healthcare

Compensation Overview

$75k - $88kAnnually

Junior

Cambridge, MA, USA

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • BA/MA in cell biology or molecular biology, with an emphasis in stem cell biology or neuroscience, and at least 2 years of practical laboratory experience, whether full-time or while in training
  • Experience in flow cytometry, including sorting of cells based on fluorescent labels
  • Experience with single cell genomic assays such as 10x Genomics platforms is required
  • Excellent interpersonal, communicative, and problem-solving skills
  • Proficiency with MS Office, and with standard programs for statistical analysis (e.g., GraphPad Prism) and flow cytometry analysis and quantification (e.g., FlowJo)
  • Demonstrate the ability to act independently and with initiative, while integrating effectively into a larger team to advance shared goals.
Responsibilities
  • Perform DNA and RNA-based genomic assays, including both bulk and single cell genomic and epigenomic approaches
  • Capture and analyze cell samples – both from culture and dissected tissues - using flow cytometry, fluorescence activated cell sorting, and histological approaches
  • Establish and process sequencing libraries for transcriptomic and epigenetic analysis
  • Assure the quality, integrity, and documentation of all data collection including compliance with all relevant lab safety and biosafety regulations.

Sana Biotechnology develops engineered cells aimed at treating and potentially curing various diseases by addressing their root causes. Their approach involves repairing and controlling genes within cells or replacing damaged or missing cells, which can lead to new types of medicines that improve patient outcomes. The company primarily serves healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. Unlike many competitors, Sana focuses heavily on research and development of cellular therapies, monetizing their innovations through licensing agreements and partnerships. Their goal is to create effective treatments for a wide range of diseases, enhancing patient care and outcomes.

Company Stage

IPO

Total Funding

$865M

Headquarters

Seattle, Washington

Founded

2018

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-16%

2 year growth

-26%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sana's recent FDA clearance for investigational new drug applications, such as SC262 and SC291, indicates promising progress in their clinical trials.
  • The company's ability to raise significant funds through PIPE offerings and public stock offerings demonstrates strong investor confidence and financial stability.
  • Expansion into key biotech hubs like Cambridge, MA, suggests growth opportunities and access to top-tier talent.

What critics are saying

  • The resignation of key executives like Dr. Douglas Williams could disrupt R&D momentum and strategic direction.
  • High competition in the biotechnology sector, especially in gene and cell therapy, may impact market share and revenue growth.

What makes Sana Biotechnology unique

  • Sana Biotechnology focuses on engineered cells to treat and potentially cure diseases at their genetic and cellular roots, setting it apart from traditional pharmaceutical approaches.
  • Their heavy investment in R&D and partnerships with pharmaceutical companies and research institutions provide a robust pipeline for innovative therapies.
  • Sana's hypoimmune platform, which aims to create cells that can 'hide' from the patient's immune system, is a unique technological advancement in the field.